Cited 210 times in
Poor Outcome of Hormone Receptor–Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea—A Report From the Korean Breast Cancer Society
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승일 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 고승상 | - |
dc.date.accessioned | 2014-12-21T16:44:35Z | - |
dc.date.available | 2014-12-21T16:44:35Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96268 | - |
dc.description.abstract | PURPOSE: Breast cancer in very young women (age < 35 years) is uncommon and poorly understood. We sought to evaluate the prognosis and treatment response of these patients compared with women ages 35 to 50 years. PATIENTS AND METHODS: We analyzed data from 9,885 breast cancer patients age < or = 50 years who were part of the Korean Breast Cancer Society registration program between 1992 and 2001. The overall survival (OS) and breast cancer-specific survival (BCSS) were compared between age groups. RESULTS: One thousand four hundred forty-four patients (14.6%) were younger than age 35 and 8,441 (85.4%) patients were between 35 and 50 years of age. Younger patients had significantly higher T-stage and higher lymph node positivity and lower hormone receptor expression than older patients. Younger patients had a greater probability of death than older patients, regardless of tumor size or lymph node status. The survival difference was significant for patients with positive or unknown hormone receptor status (P < .0001), but not for patients with negative hormone receptor status. In a multivariate analysis, the interaction term of young age and hormone receptor positivity was significant for OS and BCSS with a hazard ratio for OS of 2.13 (95% CI, 1.52 to 2.98). The significant survival benefit from adjuvant hormone therapy after chemotherapy observed in older patients (hazard ratio for OS, 0.61; 95% CI, 0.47 to 0.79; P = .001) could not be seen in younger patients (P > .05). CONCLUSION: Younger patients (age < 35) showed worse prognosis than older patients (age, 35 to 50 years) only in the hormone receptor-unknown or hormone receptor-positive subgroups. Adjuvant tamoxifen therapy might provide less survival benefit when added to chemotherapy in very young breast cancer patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 2360~2368 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Breast Neoplasms/metabolism | - |
dc.subject.MESH | Breast Neoplasms/mortality* | - |
dc.subject.MESH | Drug Resistance, Neoplasm* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Korea | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Receptors, Estrogen/metabolism* | - |
dc.subject.MESH | Receptors, Progesterone/metabolism* | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Selective Estrogen Receptor Modulators/therapeutic use | - |
dc.subject.MESH | Tamoxifen/therapeutic use* | - |
dc.title | Poor Outcome of Hormone Receptor–Positive Breast Cancer at Very Young Age Is Due to Tamoxifen Resistance: Nationwide Survival Data in Korea—A Report From the Korean Breast Cancer Society | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Sei Hyun Ahn | - |
dc.contributor.googleauthor | Byung Ho Son | - |
dc.contributor.googleauthor | Wonshik Han | - |
dc.contributor.googleauthor | Seung-Sang Ko | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Seok Won Kim | - |
dc.identifier.doi | 10.1200/JCO.2006.10.3754 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A00122 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 17515570 | - |
dc.identifier.url | http://jco.ascopubs.org/content/25/17/2360.long | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Jeong, Joon | - |
dc.contributor.alternativeName | Ko, Seung Sang | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Jeong, Joon | - |
dc.contributor.affiliatedAuthor | Ko, Seung Sang | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 25 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 2360 | - |
dc.citation.endPage | 2368 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.25(17) : 2360-2368, 2007 | - |
dc.identifier.rimsid | 35023 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.